269 related articles for article (PubMed ID: 34746121)
1. Aberrant Phase Separation of FUS Leads to Lysosome Sequestering and Acidification.
Trnka F; Hoffmann C; Wang H; Sansevrino R; Rankovic B; Rost BR; Schmitz D; Schmidt HB; Milovanovic D
Front Cell Dev Biol; 2021; 9():716919. PubMed ID: 34746121
[TBL] [Abstract][Full Text] [Related]
2. Mechanism underlying liquid-to-solid phase transition in fused in sarcoma liquid droplets.
Li S; Yoshizawa T; Shiramasa Y; Kanamaru M; Ide F; Kitamura K; Kashiwagi N; Sasahara N; Kitazawa S; Kitahara R
Phys Chem Chem Phys; 2022 Aug; 24(32):19346-19353. PubMed ID: 35943083
[TBL] [Abstract][Full Text] [Related]
3. Loss of Dynamic RNA Interaction and Aberrant Phase Separation Induced by Two Distinct Types of ALS/FTD-Linked FUS Mutations.
Niaki AG; Sarkar J; Cai X; Rhine K; Vidaurre V; Guy B; Hurst M; Lee JC; Koh HR; Guo L; Fare CM; Shorter J; Myong S
Mol Cell; 2020 Jan; 77(1):82-94.e4. PubMed ID: 31630970
[TBL] [Abstract][Full Text] [Related]
4. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay.
Kamelgarn M; Chen J; Kuang L; Jin H; Kasarskis EJ; Zhu H
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11904-E11913. PubMed ID: 30455313
[TBL] [Abstract][Full Text] [Related]
5. ALS-associated mutant FUS inhibits macroautophagy which is restored by overexpression of Rab1.
Soo KY; Sultana J; King AE; Atkinson R; Warraich ST; Sundaramoorthy V; Blair I; Farg MA; Atkin JD
Cell Death Discov; 2015; 1():15030. PubMed ID: 27551461
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
7. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis.
Blair IP; Williams KL; Warraich ST; Durnall JC; Thoeng AD; Manavis J; Blumbergs PC; Vucic S; Kiernan MC; Nicholson GA
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):639-45. PubMed ID: 19965854
[TBL] [Abstract][Full Text] [Related]
8. Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways.
Blokhuis AM; Koppers M; Groen EJN; van den Heuvel DMA; Dini Modigliani S; Anink JJ; Fumoto K; van Diggelen F; Snelting A; Sodaar P; Verheijen BM; Demmers JAA; Veldink JH; Aronica E; Bozzoni I; den Hertog J; van den Berg LH; Pasterkamp RJ
Acta Neuropathol; 2016 Aug; 132(2):175-196. PubMed ID: 27164932
[TBL] [Abstract][Full Text] [Related]
9. Emerging Roles for Phase Separation of RNA-Binding Proteins in Cellular Pathology of ALS.
Milicevic K; Rankovic B; Andjus PR; Bataveljic D; Milovanovic D
Front Cell Dev Biol; 2022; 10():840256. PubMed ID: 35372329
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS.
Kamelgarn M; Chen J; Kuang L; Arenas A; Zhai J; Zhu H; Gal J
Biochim Biophys Acta; 2016 Oct; 1862(10):2004-14. PubMed ID: 27460707
[TBL] [Abstract][Full Text] [Related]
11. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation.
Patel A; Lee HO; Jawerth L; Maharana S; Jahnel M; Hein MY; Stoynov S; Mahamid J; Saha S; Franzmann TM; Pozniakovski A; Poser I; Maghelli N; Royer LA; Weigert M; Myers EW; Grill S; Drechsel D; Hyman AA; Alberti S
Cell; 2015 Aug; 162(5):1066-77. PubMed ID: 26317470
[TBL] [Abstract][Full Text] [Related]
12. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
[TBL] [Abstract][Full Text] [Related]
13. The fused in sarcoma protein forms cytoplasmic aggregates in motor neurons derived from integration-free induced pluripotent stem cells generated from a patient with familial amyotrophic lateral sclerosis carrying the FUS-P525L mutation.
Liu X; Chen J; Liu W; Li X; Chen Q; Liu T; Gao S; Deng M
Neurogenetics; 2015 Jul; 16(3):223-31. PubMed ID: 25912081
[TBL] [Abstract][Full Text] [Related]
14. Elevated FUS levels by overriding its autoregulation produce gain-of-toxicity properties that disrupt protein and RNA homeostasis.
Ho WY; Ling SC
Autophagy; 2019 Sep; 15(9):1665-1667. PubMed ID: 31230528
[TBL] [Abstract][Full Text] [Related]
15. ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation.
Sama RR; Fallini C; Gatto R; McKeon JE; Song Y; Rotunno MS; Penaranda S; Abdurakhmanov I; Landers JE; Morfini G; Brady ST; Bosco DA
Sci Rep; 2017 Mar; 7(1):115. PubMed ID: 28273913
[TBL] [Abstract][Full Text] [Related]
16. Aggregation of ALS-linked FUS mutant sequesters RNA binding proteins and impairs RNA granules formation.
Takanashi K; Yamaguchi A
Biochem Biophys Res Commun; 2014 Sep; 452(3):600-7. PubMed ID: 25173930
[TBL] [Abstract][Full Text] [Related]
17. Mutant FUS and ELAVL4 (HuD) Aberrant Crosstalk in Amyotrophic Lateral Sclerosis.
De Santis R; Alfano V; de Turris V; Colantoni A; Santini L; Garone MG; Antonacci G; Peruzzi G; Sudria-Lopez E; Wyler E; Anink JJ; Aronica E; Landthaler M; Pasterkamp RJ; Bozzoni I; Rosa A
Cell Rep; 2019 Jun; 27(13):3818-3831.e5. PubMed ID: 31242416
[TBL] [Abstract][Full Text] [Related]
18. Directly converted patient-specific induced neurons mirror the neuropathology of FUS with disrupted nuclear localization in amyotrophic lateral sclerosis.
Lim SM; Choi WJ; Oh KW; Xue Y; Choi JY; Kim SH; Nahm M; Kim YE; Lee J; Noh MY; Lee S; Hwang S; Ki CS; Fu XD; Kim SH
Mol Neurodegener; 2016 Jan; 11():8. PubMed ID: 26795035
[TBL] [Abstract][Full Text] [Related]
19. Liquid-Liquid Phase Separation of TDP-43 and FUS in Physiology and Pathology of Neurodegenerative Diseases.
Carey JL; Guo L
Front Mol Biosci; 2022; 9():826719. PubMed ID: 35187086
[TBL] [Abstract][Full Text] [Related]
20. Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA-binding proteins with prion-like domains.
Guo L; Mann JR; Mauna JC; Copley KE; Wang H; Rubien JD; Odeh HM; Lin J; Lee BL; Ganser L; Robinson E; Kim KM; Murthy AC; Paul T; Portz B; Gleixner AM; Diaz Z; Carey JL; Smirnov A; Padilla G; Lavorando E; Espy C; Shang Y; Huang EJ; Chesi A; Fawzi NL; Myong S; Donnelly CJ; Shorter J
bioRxiv; 2023 Sep; ():. PubMed ID: 37732211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
